Because the drugs reduce cancer recurrence, finding a way to help patients stay on them is important for long-term, relapse-freesurvival, according to Rastelli.
Determined that patients with diffuse large B cell lymphoma had high serum levels of miR-21, which associated with increased relapse-freesurvival 3. Around the same time, Mitchell et al.
They also observed that in 28% of patients predicted to be sensitive to treatment, 3-year distant relapse-freesurvival (DRFS) was 92%, with a significant absolute risk reduction of 18%.